Key insights
- Citizens reiterated an outperform rating on Abivax (ABVX) based on positive trial data expectations. Other analysts have mixed views, with some highlighting the potential of obefazimod and others expressing caution about M&A. Takeover speculation involving AstraZeneca and Eli Lilly has surfaced, though denied by Abivax. Overall, analyst sentiment is mixed, with a slight positive bias, but the impact on the broader US market is limited.
Investing.com - Citizens reiterated a Market Outperform rating and $131.00 price target on Abivax (NASDAQ:ABVX) shares. The stock currently trades at $115.42, down from its previous close of $120.34, though it has delivered a remarkable 1,466% return over the past year.
The firm said top-line results from the ongoing Phase 3 ABTECT-UC trial are anticipated in late-2Q26. Citizens said it continues to believe in the potential for positive results, supported by the robust responder rate demonstrated in the induction phase, as well as the Phase 2b long-term extension results.
The safety review conducted by the independent Data Safety Monitoring Board was completed on March 18, 2026. The board found no new safety signals.
Citizens said the assessment reinforces its confidence in the candidate’s clean safety profile. The firm noted the most recent DSMB assessment included all randomized patients in the Phase 3 maintenance trial.
Nearly 90% of patients have completed the 44-week trial, according to the firm.
In other recent news, Abivax has attracted attention from various analysts and investors. Piper Sandler reiterated an Overweight rating on Abivax with a price target of $165, emphasizing expectations for upcoming Phase 3 maintenance data for ulcerative colitis. Jefferies initiated coverage with a buy rating and a $160 price target, noting the potential of Abivax’s obefazimod drug candidate. In contrast, Wedbush started coverage with an Underperform rating and a $110 price target, citing caution regarding mergers and acquisitions.
Citizens maintained a Market Outperform rating with a $131 price target after Abivax presented 22 abstracts at a European medical conference. Meanwhile, speculation about potential takeover bids has resurfaced, with reports suggesting AstraZeneca might offer €176 per share for Abivax, valuing the company at approximately €13.75 billion. This follows earlier rumors of a possible €15 billion offer from Eli Lilly, although Abivax has denied these claims. These developments highlight the varied perspectives among analysts and the market’s interest in Abivax’s strategic moves.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.